Clinical Trial Update: A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection [Phase 1, Phase 2]

View source ↗

Summary

A double-blind, active-controlled Phase 1/2 study of aerosolized RSP-1502 in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection, curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Infection

Drugs mentioned

• RSP-1502 (RSP-1502)

Snippet

Sponsor: Respirion Pharmaceuticals Pty Ltd | Conditions: Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic | Phase 1, Phase 2 | Status: RECRUITING